Follow Us on Social Media!
Tokyo, Japan, October 15, 2012
—IFC, a member of the World Bank Group, has presented Hikma Pharmaceuticals with its 2012 Client Leadership Award which recognizes companies that show a commitment to sustainable development, innovation, operational excellence, and strong corporate governance.
IFC CEO and Executive Vice President Jin-Yong Cai presented the award to Mazen Darwazah, Hikma Vice Chairman and CEO of the Middle East and North Africa region, during a ceremony in Tokyo. Headquartered in Jordan, Hikma has more than 6,500 employees and sales in some 50 countries. The Middle East’s biggest pharmaceutical manufacturer, it was recognized for providing affordable, life-saving medicine to people around the world. It was also lauded for its strong corporate governance and internal efforts that support female workers, encourage recycling, and provide internships to young Jordanians.
“This is award is a testament to the work we have done over the last 30 years to turn Hikma into a world-class company,” said Darwazah. “I think it also shows that companies that focus on being good corporate citizens will also have success.”
IFC has a long-term relationship with Hikma. Since 1987, IFC has invested $165 million in the company, a total that includes both loans and share purchases. It has also provided Hikma with advice in areas from corporate governance to environmental management.
“Hikma is not only providing affordable medicines to millions—it is also setting the standard for corporate social responsibility in the Middle East and North Africa,” Cai said. “Our partnership of more than 20 years with Hikma demonstrates how the private sector can spark change in the region and make a difference in people’s lives.”
The partnership with Hikma is part of IFC’s efforts in the Middle East and North Africa to encourage development by supporting the private sector. Our investments reached a record $2.9 billion during the last fiscal year, including $754 million in mobilization. We also launched 27 advisory projects with a total value of $20.2 million.
IFC, a member of the World Bank Group is the largest global development institution focused exclusively on the private sector. We help developing countries achieve sustainable growth by financing investment, mobilizing capital in international financial markets, and providing advisory services to businesses and governments. In FY12, our investments reached an all-time high of more than $20 billion, leveraging the power of the private sector to create jobs, spark innovation, and tackle the world’s most pressing development challenges. For more information, visit
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing, and marketing a broad range of both branded and non
branded generic and licensed products. Hikma's operations are conducted through three businesses: Branded, Injectables, and Generics. It is based principally in the Middle East and North Africa , where it is a market leader, the United States, and Europe. In 2011, Hikma achieved revenues of $918 million and a profit attributable to shareholders of $80.3 million. For more information, visit
Receive news and updates about IFC